淋巴瘤化疗诱发肝衰竭患者临床特点与预后分析

doi:10.3969/j.issn.1672-5069.2021.03.020

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (3): 383-386.doi: 10.3969/j.issn.1672-5069.2021.03.020

淋巴瘤化疗诱发肝衰竭患者临床特点与预后分析

刘松涛, 孟庆华, 闾军, 刘梅, 许媛, 周建新, 胡中杰

100069 北京市首都医科大学附属北京佑安医院肝病重症医学科(刘松涛,孟庆华,胡中杰);
肿瘤内科(闾军,刘梅);
首都医科大学附属北京天坛医院重症医学科(周建新);
北京清华长庚医院重症医学科(许媛)

收稿日期:2020-07-10 出版日期:2021-05-30 发布日期:2021-04-30
通讯作者: 胡中杰,E-mail:yfcyt@139.com
作者简介:刘松涛,男,39岁,医学硕士,主治医师。主要从事感染性危重症的诊断和治疗学研究。E-mail:botao8080@163.com
基金资助:
中国初级卫生保健基金会-佑安肝病艾滋病基金资助项目(编号:BJYAYY-GG2019-01)

Clinical feature and prognosis of lymphoma patients with chemotherapy-induced liver failure

Liu Songtao, Meng Qinghua, Lyu Jun, et al

Department of Severe Liver Disease, You'an Hospital, Capital Medical University, Beijing 100069, China

Received:2020-07-10 Online:2021-05-30 Published:2021-04-30

摘要/Abstract

摘要： 目的总结因淋巴瘤化疗后发生肝衰竭患者的病历资料,分析其发生肝衰竭的原因和影响结局的因素,以提高临床诊治能力。方法采用回顾性分析法总结21例接受化疗的淋巴瘤患者在发生肝衰竭后的临床特点治疗经过和预后变化。结果在21例患者中,非霍奇金淋巴瘤20例,霍奇金淋巴瘤1例;接受利妥昔单抗和化疗药物化疗;诱发肝衰竭的原因为HBV感染激活12例,药物性肝损伤5例,淋巴瘤肝脏浸润2例,HEV感染2例;常规综合措施护肝治疗,结果11例生存,10例死亡【中位生存时间为14(4～40) d】;单因素分析显示生存与死亡患者血清AST、Cr、INR和MELD评分存在显著性差异(P<0.05),经Cox回归生存分析显示Cr和MELD评分是影响死亡的独立危险因素。结论淋巴瘤患者在接受化疗期间需密切监测病毒学和肝功能变化,对合并HBV感染者,应及时预防性应用抗病毒药物。

关键词: 肝衰竭, 淋巴瘤, 临床特征, 预后

Abstract: Objective The aim of this summarize the clinical feature and prognostic factors of patients with liver failure induced by chemotherapy for lymphoma.Methods The clinical manifestations, laboratory tests and outcomes of liver failure after chemotherapy for lymphoma were analyzed retrospectively.Results 21 patients (15 males and 6 females) were included with the mean age of 55.6±15.2(29-76) years old, having underlying non-Hodgkin’s lymphoma in 20 cases and Hodgkin’s lymphoma in one; the rituximab and conventional chemotherapy were given, and the causes of liver failure were hepatitis B viral reactivation in 12, drug-induced liver injury in 5, hepatic lymphoma infiltration in 2 and hepatitis E infection in 2; all patients received conventional supporting therapy including artificial liver supporting system; 11 patients survived and 10 died with median survival of 14(4 -40) days; univariate analysis showed that serum AST, Cr, INR and MELD score were the risk factors of death, and Cox regression showed that serum Cr and the MELD score were the independent impacting predictors. Conclusions The liver function tests should be closely monitored in patients with lymphoma during chemotherapy, and antiviral therapy should be started prophylactically in patients with underlying HBV infection.

Key words: Liver failure, Lymphoma, Clinical feature, Prognosis

刘松涛, 孟庆华, 闾军, 刘梅, 许媛, 周建新, 胡中杰. 淋巴瘤化疗诱发肝衰竭患者临床特点与预后分析[J]. 实用肝脏病杂志, 2021, 24(3): 383-386.

Liu Songtao, Meng Qinghua, Lyu Jun, et al. Clinical feature and prognosis of lymphoma patients with chemotherapy-induced liver failure[J]. Journal of Practical Hepatology, 2021, 24(3): 383-386.

参考文献

[1] Wijaya I, Sanityoso A, Lesmana LA. Acute liver failure related to chemotherapy. Acta Med Indones, 2012, 44(2):145-149.
[2]Noterdaeme T, Longrée L, Bataille C, et al. Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients. World J Gastroenterol, 2011, 17(25):3069-3072.
[3] 叶伟, 杜建霞, 张宁, 等. 利妥昔单抗治疗淋巴瘤患者致乙型肝炎病毒再激活一例. 中华传染病杂志, 2016, 34(6):369-370.
[4] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016, 127(20):2391-2405.
[5] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 实用肝脏病杂志, 2019, 22(2):164-171.
[6] Song C, Lyu J, Liu Y, et al. Associations between hepatitis B virus infection and risk of all cancer types. JAMA Netw Open, 2019, 2(6):e195718.
[7] Zhou X, Pan H, Yang P, et al. Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma. BMC Cancer, 2019, 19(1):477.
[8] Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol, 2010, 11(9):827-834.
[9] Zurawska U, Hicks LK, Woo G, et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol, 2012, 30(26):3167-3173.
[10] Tsai YF, Yang CI, Du JS, et al. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study. Peer J, 2019,7:e7481.
[11] Kusumoto S, Arcaini L, Hong X, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood, 2019,133(2):137-146..
[12] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020, 23(1):161-184.
[13] Arora A, Anand AC, Kumar A, et al. INASL guidelines on management of hepatitis B virus infection in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids. J Clin Exp Hepatol, 2018, 8(4):403-431.
[14] 宋芳娇, 朱冰, 吕飒, 等. 314例药物性肝衰竭患者临床特征分析. 实用肝脏病杂志, 2019, 22(2):216-219.
[15] 吴欣, 郭杨志, 杜霄壤, 等. 75例中药诱导的肝损伤患者临床特征分析. 实用肝脏病杂志, 2019, 22(5):668-671.
[16] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology, 2019, 156(8):2230-2241.
[17] Shimazu Y, Nohgawa M. DLBCL developed into fatal liver failure during rituximab-containing chemotherapy. J Clin Exp Hematop, 2019, 59(2):93-95.
[18] Cai J, Wang K, Han T, et al. Evaluation of prognostic values of inflammation-based makers in patients with HBV-related acute-on-chronic liver failure. Medicine (Baltimore), 2018, 97(46):e13324.
[19] Xiao LL, Xu XW, Huang KZ, et al. Artificial liver support system improves short-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a propensity score analysis. Biomed Res Int, 2019, 2019:3757149.
[20] Lu TX, Wu S, Cai DY, et al. Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma. BMC Cancer, 2019, 19(1):553.

淋巴瘤化疗诱发肝衰竭患者临床特点与预后分析

Clinical feature and prognosis of lymphoma patients with chemotherapy-induced liver failure

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王梦雨, 杨蕊旭, 范建高. 重视代谢相关脂肪性肝病的特征与预后临床研究^*[J]. 实用肝脏病杂志, 2021, 24(3): 308-311.
[2]	林列坤, 卢春生, 周应生, 郑义, 杨菊红, 邹继彬, 张仁超, 梁旭竞. 慢加急性肝衰竭小鼠肝组织组蛋白去乙酰化酶mRNA水平变化[J]. 实用肝脏病杂志, 2021, 24(3): 327-330.
[3]	陈晨, 王联发, 王艳, 唐郡, 张骏飞, 黄猛珣, 刘波. 112例新型冠状病毒肺炎患者肝肾功能和心肌酶学变化分析[J]. 实用肝脏病杂志, 2021, 24(3): 351-354.
[4]	孔雪杰, 李江, 李昊天, 李绪桐, 郜玉峰. 不同肝病基础的慢加急性肝衰竭患者临床特征和预后评分模型预测效能比较[J]. 实用肝脏病杂志, 2021, 24(3): 387-390.
[5]	苏亚勇, 徐成润, 郭永木, 张惠勇, 刘双平, 陈小兰. 慢加急性乙型肝炎肝衰竭患者死亡危险因素和预后评分模型的构建[J]. 实用肝脏病杂志, 2021, 24(3): 391-394.
[6]	高慧茹, 高会斌, 彭昭, 王璐, 霍小辉. 乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者临床特征及影响因素分析[J]. 实用肝脏病杂志, 2021, 24(3): 395-398.
[7]	李华, 温江华, 吴英春, 潘宇翔. 酒精性肝硬化患者临床特征分析[J]. 实用肝脏病杂志, 2021, 24(3): 411-414.
[8]	党玲, 贾皑, 王芳. 血清内毒素结合蛋白和sCD163水平预测亚急性肝衰竭患者预后的价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 447-448.
[9]	张维娜, 丁传刚, 赵红英, 李丽, 张曼军, 卢旭. 巨细胞病毒性肝炎患儿血清IFN-γ和IL-18水平变化及其与预后的关系探讨[J]. 实用肝脏病杂志, 2021, 24(2): 208-211.
[10]	王江丽, 裴凌燕, 贺晶晶, 李岚, 袁佳健, 夏莉婷, 崔雯. 血清PTX3和sTWEAK预测失代偿期乙型肝炎肝硬化患者死亡临床价值分析[J]. 实用肝脏病杂志, 2021, 24(2): 236-239.
[11]	孙文霞, 伍树芝. IgG4相关性硬化性胆管炎100例临床特征分析[J]. 实用肝脏病杂志, 2021, 24(1): 83-86.
[12]	魏荣荣, 李爱玲, 李红, 张缭云. 慢性肝炎肝硬化和肝衰竭患者吲哚菁绿清除试验的变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 91-94.
[13]	刘振, 潘光栋, 周峥, 刘强, 梁越, 黄科团, 郝树青, 杨建青. 肝细胞癌组织COPB2基因水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(1): 115-118.
[14]	张健荣, 顾尔莉, 王忠成, 施亚军. 自身免疫性肝炎、原发性胆汁性胆管炎及其重叠综合征患者临床特征比较^*[J]. 实用肝脏病杂志, 2020, 23(6): 829-832.
[15]	关万涛, 康福新, 林维, 林宏云, 黎仕焕. CRRT联合PE治疗慢加急性乙型肝炎肝衰竭并发急性肾损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(6): 833-836.